Wednesday, November 21, 2012

• 5 Stocks Pushing The Health Care Sector Lowerat TheStreet (Wed, Nov 21)

Tuesday, November 20, 2012

• New Second Generation Combination Therapy For HCV - First Or Best In The Market - Part 2at Seeking Alpha (Tue, Nov 20)

Monday, November 19, 2012

• FDA Approval Victory a Yawner?at Motley Fool (Mon, Nov 19)
• Vertex Pharmaceuticals Stock Hold Recommendation Reiterated (VRTX)at TheStreet (Mon, Nov 19)

Friday, November 16, 2012

• Vertex Announces Webcasts of its Presentations at Two Investor ConferencesBusiness Wire (Fri, Nov 16)
• Pessimism On Vertex Pharmaceuticals Increases, Erasing Previous Gainsat Seeking Alpha (Fri, Nov 16)

Thursday, November 15, 2012

• Are Arena and VIVUS Frenemies?at Motley Fool (Thu, Nov 15)
• Regeneron Pharmaceuticals Among Healthcare's Biggest Movers on November 15, 2012at Investopedia (Thu, Nov 15)

Wednesday, November 14, 2012

• Vertex Pharmaceuticals Among Healthcare's Biggest Movers on November 14, 2012at Investopedia (Wed, Nov 14)

Tuesday, November 13, 2012

• Gilead May Move Ahead of Rivals With Hepatitis C Resultsat Bloomberg (Tue, Nov 13)
• Analysts tout advantage of Gilead hepatitis C drugAP (Tue, Nov 13)
• 3 Reasons Why Not All Hep C Data Is Created Equalat Motley Fool (Tue, Nov 13)
• Direction Change Ahead, What to Expect - Research & Analysis on Achillion Pharmaceuticals, Inc. and Vertex Pharmaceuticals IncorporatedMarketwired (Tue, Nov 13)
• Why Shares of Gilead Sciences Popped and Achillion Pharmaceuticals Droppedat Motley Fool (Tue, Nov 13)
• Gilead Hits the Jackpot with HCV Drugat Motley Fool (Tue, Nov 13)

Monday, November 12, 2012

• Vertex Pharmaceuticals (VRTX): Today's Featured Health Care Laggardat TheStreet (Mon, Nov 12)
• Gilead Climbs on Study Results of Hepatitis C Combinationat Bloomberg (Mon, Nov 12)
• Hep C Competitors Cede Space To Gilead And Bristol-Myers And Turn To Niche Usesat Seeking Alpha (Mon, Nov 12)
• Analyst Moves: JCP, VRTXat Forbes (Mon, Nov 12)
• OraSure Reports Weak Q3 and 3 Stock Analyses to See Nowat Wall St. Cheat Sheet (Mon, Nov 12)
• New Developments At Abbott Labsat Motley Fool (Mon, Nov 12)
• Snag This Deal Even Lower Than Director McGlynn Didat Forbes (Mon, Nov 12)
• Gilead Shares Rise on Hepatitis C Treatmentat Minyanville (Mon, Nov 12)
• 100%! Gilead's Perfect Results One-Up Abbottat Motley Fool (Mon, Nov 12)

Sunday, November 11, 2012

• Vertex announced data on on ALS-2200 are being presented at AASLDtheflyonthewall.com (Sun, Nov 11)

Add VRTX News to My Yahoo!